|Drug class||Long-acting muscarinic antagonist (LAMA)|
|Main uses||Chronic obstructive pulmonary disease (COPD)|
|Side effects||Cough, upper respiratory tract infection, headache, back pain|
|Typical dose||175 ucg (3 mL) OD|
|Chemical and physical data|
|Molar mass||597.760 g·mol−1|
|3D model (JSmol)|
Common side effects include cough, upper respiratory tract infection, headache, and back pain. Other side effects may include allergic reactions, bronchospasm, and urinary retention. It is a long-acting muscarinic antagonist (LAMA).
Revefenacin was approved for medical use in the United States in 2018. It is not available in the United Kingdom or Europe as of 2021. In the United States it costs about 1,100 USD per month.
It is taken at a dose of 175 mcg (3 mL) once per day.
- "Revefenacin Monograph for Professionals". Drugs.com. Archived from the original on 17 April 2021. Retrieved 16 October 2021.
- "DailyMed - YUPELRI- revefenacin solution". dailymed.nlm.nih.gov. Archived from the original on 4 August 2020. Retrieved 17 October 2021.
- "Revefenacin". SPS - Specialist Pharmacy Service. 28 December 2015. Archived from the original on 17 October 2021. Retrieved 17 October 2021.
- "Yupelri Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 17 October 2021.
- Heo YA (January 2019). "Revefenacin: First Global Approval". Drugs. 79 (1): 85–91. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.